While BTK inhibitors are emerging drugs that promote apoptosis in DLBCL [36], the BCR signal suppression in CD5-positive DLBCL may make these cells resistant to BTK inhibitors. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.